Transient expression of RNA for CAR T-cell therapies: An emerging opportunity for lipid nanoparticles
By enabling messenger RNA (mRNA) delivery for transient protein expression with minimal toxicity, lipid nanoparticles have the potential to address a range of manufacturing and safety challenges facing the CAR T-cell therapy field. As new studies are published demonstrating their advantages, it may not be long before LNPs start to displace electroporation in the non-viral CAR T delivery field.
